Guilherme Harada

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 17 papers. Top paper: “Rare molecular subtypes of lung cancer”.

Rare molecular subtypes of lung cancer

Nature Reviews Clinical Oncology(2023)10.1038/s41571-023-00733-6

N/A

0.721DataRank · unranked

121 citations

Soo‐Ryum Yang, Emiliano Cocco, Alexander Drilon, Guilherme Harada

Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors

The Oncologist(2025)10.1093/oncolo/oyaf017

N/A

0.473DataRank · unranked

11 citations

Yonina R. Murciano‐Goroff, Antoine Desîlets, Guilherme Harada, Michael A. Postow, Margaret K. Callahan +9 more

TRK Inhibitors in Non-Small Cell Lung Cancer

Current Treatment Options in Oncology(2020)10.1007/s11864-020-00741-z

N/A

0.449DataRank · unranked

19 citations

Aline Bobato Lara Gongora, Cesar Martins da Costa, Fernando Costa Santini, Guilherme Harada

Mechanisms of acquired resistance to TRK inhibitors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3104

N/A

0.442DataRank · unranked

18 citations

Noura J. Choudhury, Alison M. Schram, Ezra Y. Rosen, Yonina R. Murciano‐Goroff, Christina J. Falcon +13 more

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

npj Precision Oncology(2024)10.1038/s41698-024-00663-1

N/A

0.345DataRank · unranked

9 citations

Matteo Repetto, Clare Keddy, Katelyn S. Nicholson, Kristen L. Jones, Kevin D. Nusser +5 more

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib

JCO Precision Oncology(2023)10.1200/po.23.00295

N/A

0.315DataRank · unranked

5 citations

Biagio Ricciuti, Guilherme Harada, Matteo Repetto, Melissa Gildenberg, Ankit Singh +16 more

Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.03.045

N/A

0.292DataRank · unranked

6 citations

Federica Pecci, Biagio Ricciuti, Felix H. Gottlieb, Francesco Facchinetti, Guilherme Harada +21 more

Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.11.010

N/A

0.269DataRank · unranked

5 citations

Rohit Thummalapalli, Christopher A. Febres‐Aldana, Daniel M. Muldoon, Christina J. Falcon, Amanda Pupo +18 more

Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9080

N/A

0.208DataRank · unranked

3 citations

Christina J. Falcon, Christine M. Bestvina, Dazhi Liu, Lauren A. Kaplanis, Clare Wilhelm +11 more

ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3062

N/A

0.165DataRank · unranked

2 citations

Guilherme Harada, Noura J. Choudhury, Casey Savin, Ronak Shah, Michael F. Berger +2 more

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

British Journal of Cancer(2024)10.1038/s41416-024-02760-1

N/A

0DataRank · unranked

13 citations

Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina +17 more

An Ascendant Challenge: Central Nervous System Metastases in ALK + Lung Cancers

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0341

N/A

0DataRank · unranked

3 citations

Guilherme Harada, Alexander Drilon, Yonina R. Murciano‐Goroff

Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to “False” Decreases in Renal Function

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.09.1444

N/A

0DataRank · unranked

32 citations

Guilherme Harada, Dazhi Liu, Ray DeMatteo, Christina J. Falcon, Clare Wilhelm +4 more

Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.06.008

N/A

0DataRank · unranked

47 citations

Christina J. Falcon, Christine M. Bestvina, Dazhi Liu, Lauren A. Kaplanis, Clare Wilhelm +12 more

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.01.16.575901

N/A

0DataRank · unranked

3 citations

Matteo Repetto, Clare Keddy, Katelyn S. Nicholson, Kristen L. Jones, Kevin D. Nusser +5 more

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100792

N/A

0DataRank · unranked

3 citations

Rose Parisi, Guilherme Harada, Andrea P. Moy, George Dranitsaris, Jasmine H. Francis +7 more

A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100857

N/A

0DataRank · unranked

0 citations

Fernando C. Santini, Clare Wilhelm, Rebecca W Repetti, Jason C. Chang, Soo-Ryum Yang +10 more